Application of CAPTURE Assay for Early Diagnosis and Prognosis in Bile and Blood of Cholangiocarcinoma
JCO Precision Oncology · 2025
DOI: 10.1200/po-24-00728 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Yi-Cheng Tsai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Power Mechanical Engineering, National Tsing Hua University, Hsinchu, Taiwan. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Neoplastic Cells, Circulating, Bile. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Cholangiocarcinoma (CCA) is highly metastatic, difficult to diagnose, and characterized by extremely low 5-year survival rate. Liquid biopsy is reported as a new tool for monitoring and potential diagnosis of cancers. In this study, we developed a novel approach, CAPTURE (Cancer cell affinity probing and tracked by immunoreaction) assay, using blood and bile for the detection of CCA. MATERIALS AND METHODS The CAPTURE assay isolated exfoliated tumor cells (ETCs) from bile and circulating tumor cells (CTCs) from blood of patients with CCA (CCA+) using magnetic beads coated with two affinity probes: a nucleic-acid aptamer or a glycosaminoglycan octasaccharide, followed by immunostaining to track target tumor cells-bead complexes. Target-bead complexes were quantified under a fluorescent microscope (ETCs:CK17+/CK7+/Hoechst+; CTCs: CK17+/CD45-/Hoechst+). Epithelial cell adhesion molecule was also used as a comparison. The blood and bile from patients of benign biliary-related diseases (CCA–) served as control. The study was validated in a single-blind fashion. RESULTS Finally, numbers of CTCs of blood (82 CCA+ and 48 CCA–) and ETCs of bile (132 CCA+ and 63 CCA–) samples were quantified and validated. Sensitivities and specificities were 98.5% and 85.7% with bile tests, and 96.3% and 85.4% with blood tests. Moreover, we successfully monitored prognoses of two follow-up patients using CAPTURE assay after treatments. CONCLUSION ETCs in bile could be promising indicators of disease status in early through advanced stages of CCA, whereas CTCs in blood might have crucial value in diagnosing and monitoring advanced stages of CCA. Our results showed that the CAPTURE assay would be a powerful tool in CCA diagnostics and prognostics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Power Mechanical Engineering, National Tsing Hua University, Hsinchu, Taiwan.
- Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Institute of Biomedical Engineering, National Tsing Hua University, Hsinchu, Taiwan.
- Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
- School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
ORCID-Profile: Shang-Cheng Hung, Gwo-Bin Lee
Zitieren
APA
Tsai, Y. C., Huang, C. J., Chang, J. L., Chiang, N. J., Huang, Y. S., Bandaru, A., Hung, S. C., Shan, Y. S., & Lee, G. B. (2025). Application of CAPTURE Assay for Early Diagnosis and Prognosis in Bile and Blood of Cholangiocarcinoma. JCO Precision Oncology. https://doi.org/10.1200/po-24-00728
Vancouver
Tsai YC, Huang CJ, Chang JL, Chiang NJ, Huang YS, Bandaru A, et al. Application of CAPTURE Assay for Early Diagnosis and Prognosis in Bile and Blood of Cholangiocarcinoma. JCO Precision Oncology. 2025. doi:10.1200/po-24-00728
BibTeX
@article{Tsai2025,
author = {Tsai, Yi-Cheng and Huang, Chien-Jui and Chang, Jui-Lin and Chiang, Nai-Jung and Huang, Yu-Shan and Bandaru, Anandaraju and Hung, Shang-Cheng and Shan, Yan-Shen and Lee, Gwo-Bin},
title = {Application of CAPTURE Assay for Early Diagnosis and Prognosis in Bile and Blood of Cholangiocarcinoma},
journal = {JCO Precision Oncology},
year = {2025},
doi = {10.1200/po-24-00728}
}
EUVIMED